A British Robot Breaks Into Intuitive's Turf

CMR Surgical launches Versius Plus in US hospitals and ASCs, challenging Intuitive Surgical's long grip on robotic surgery

28 May 2026

For decades, a single company has defined what a surgical robot looks like in an American operating room. Intuitive Surgical placed its da Vinci system in more than 10,670 hospitals worldwide, building an infrastructure of outcomes data and reimbursement arrangements that rivals have found nearly impossible to replicate. CMR Surgical, a British firm, is now attempting to change that.

Versius Plus received FDA clearance in December 2025 for laparoscopic cholecystectomy and began active US deployment in March 2026. The system's architecture departs from convention. Each robotic arm sits on its own moveable cart, letting surgical teams reposition equipment between rooms without lengthy recalibration. For ambulatory surgical centers, where room throughput shapes daily economics, that portability is not a minor feature.

The timing is deliberate. The US ambulatory surgery center market reached $46.51 billion in 2026 and is growing at 6.3% annually, driven by a steady migration of procedures out of inpatient settings. Capital-constrained health systems are openly reassessing fixed, high-cost robotic infrastructure, and modular platforms with phased investment models are gaining serious consideration. Medtronic's Hugo RAS is pursuing a similar path, adding competitive depth to a market that has operated with limited choice for years.

Structural barriers remain formidable. CMR's current clearance covers one procedure type. Additional FDA submissions will be required before Versius Plus can compete across a broader surgical range, and clinical evidence must accumulate before hospital purchasing committees treat it as a genuine substitute. Reputation is not borrowed easily in US procurement.

Yet the conditions for entry have rarely been more favorable. Procurement officers who once deferred reflexively to the incumbent are now asking harder questions about cost and flexibility. Whether CMR can convert that openness into durable market share depends less on its architecture than on its ability to generate clinical data at speed. The robot may be modular. The proof required is not.